DIPAL DIVECHA: Open Payments
NPI 1023351384 · SUGARLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$11,839 in 232 payments from 33 companies in 2025. Trend: 2023 $860 · 2024 $1,183 · 2025 $11,839
Speaker / faculty: $7,403Food & beverage: $4,436
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 26 | $7,820 |
| Amgen Inc. | 29 | $567 |
| Novo Nordisk Inc | 28 | $521 |
| Ascendis Pharma Endocrinology Inc | 11 | $397 |
| Corcept Therapeutics | 12 | $266 |
| BETA BIONICS, INC. | 9 | $237 |
| Lilly USA, LLC | 14 | $220 |
| Tandem Diabetes Care, Inc. | 8 | $210 |
| Dexcom, Inc. | 20 | $209 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $159 |
Products named: Omnipod, Yorvipath, JARDIANCE, Korlym, Wegovy, TEPEZZA, iLet Bionic Pancreas, Ozempic.
Industry payments across TX — which companies pay providers there.
